Loxo Oncol Drug Patent Portfolio
Loxo Oncol owns 1 orange book drug protected by 6 US patents Given below is the list of Loxo Oncol's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12109193 | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | 14 Sep, 2041 | Active |
| US10342780 | Compounds useful as kinase inhibitors | 16 Dec, 2036 | Active |
| US10464905 | Compounds useful as kinase inhibitors | 16 Dec, 2036 | Active |
| US10695323 | Compounds useful as kinase inhibitors | 16 Dec, 2036 | Active |
| US10918622 | Compounds useful as kinase inhibitors | 16 Dec, 2036 | Active |
| US12220401 | Compounds useful as kinase inhibitors | 16 Dec, 2036 | Active |
Latest Legal Activities on Loxo Oncol's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Loxo Oncol.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 14 May, 2024 | US10695323 |
| Mail Patent eCofC Notification | 14 May, 2024 | US10695323 |
| Patent eCofC Notification | 14 May, 2024 | US10695323 |
| Recordation of Patent eCertificate of Correction | 14 May, 2024 | US10695323 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US10342780 |
| Post Issue Communication - Certificate of Correction | 24 Apr, 2024 | US10695323 |
| Mail Certificate of Correction Memo | 23 Apr, 2024 | US10695323 |
| Certificate of Correction Memo | 18 Apr, 2024 | US10695323 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US10342780 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Nov, 2023 | US10695323 |
| RX - Mail Miscellaneous Communication to Applicant | 03 Aug, 2023 | US10918622 |
| Initial letter Re: PTE Application to regulating agency | 06 Jul, 2023 | US10342780 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Apr, 2023 | US10464905 |
| Patent Term Extension Application under 35 USC 156 Filed | 22 Mar, 2023 | US10342780 |
| Post Issue Communication - Certificate of Correction | 26 Jan, 2023 | US10918622 |
Loxo Oncol's Family Patents
Loxo Oncol drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 10.3% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Loxo Oncol Drug List
Given below is the complete list of Loxo Oncol's drugs and the patents protecting them.
1. Jaypirca
Jaypirca is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12109193 | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
14 Sep, 2041
(16 years from now)
| Active |
| US10342780 | Compounds useful as kinase inhibitors |
16 Dec, 2036
(11 years from now)
| Active |
| US10464905 | Compounds useful as kinase inhibitors |
16 Dec, 2036
(11 years from now)
| Active |
| US10695323 | Compounds useful as kinase inhibitors |
16 Dec, 2036
(11 years from now)
| Active |
| US10918622 | Compounds useful as kinase inhibitors |
16 Dec, 2036
(11 years from now)
| Active |
| US12220401 | Compounds useful as kinase inhibitors |
16 Dec, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jaypirca's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List